Log in to your Inderes Free account to see all free content on this page.

ContextVision

Less than 1K followers

CONTX

Oslo Børs

Medical Equipment & Services

Health Care

Overview

Ownership

Investor consensus

ContextVision is a medical technology company. The company specializes in image analysis and artificial intelligence. The company's products include advanced image enhancement software for ultrasound, MRI, X-ray and mammography. The software is used by hospitals and research institutes worldwide. The company was founded in 1983 and is headquartered in Stockholm.

Market cap

-

Turnover

-

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

19.2.

2026

Annual report '25

8.5.

2026

Interim report Q1'26

12.5.

2026

General meeting '26

All

Press releases

ShowingAll content types

Regulatory press release12/2/2025, 5:45 PM

ContextVision AB: Transactions made under the buy-back programme

Regulatory press release12/1/2025, 10:25 AM

CONTX: Financial calendar

Regulatory press release11/21/2025, 4:10 PM

ContextVision AB: Transactions made under the buy-back programme

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/12/2025, 4:11 PM

ContextVision AB: Transactions made under the buy-back programme

Regulatory press release11/6/2025, 7:00 AM

ContextVision AB: Q3 interim report 2025 – Navigating market uncertainty while making solid progress with our Data Quality initiative

Regulatory press release11/3/2025, 3:50 PM

ContextVision AB: Transactions made under the buy-back programme

Regulatory press release10/23/2025, 3:08 PM

ContextVision AB: Transactions made under the buy-back programme

Regulatory press release10/14/2025, 3:50 PM

ContextVision AB: Transactions made under the buy-back programme

Regulatory press release10/3/2025, 5:45 PM

ContextVision AB: Transactions made under the buy-back programme

Regulatory press release9/24/2025, 4:00 PM

ContextVision AB: Transactions made under the buy-back programme

Regulatory press release9/15/2025, 4:00 PM

ContextVision AB: Transactions made under the buy-back programme

Regulatory press release9/3/2025, 7:00 AM

ContextVision - Initiation of share buyback program

Regulatory press release8/26/2025, 6:00 AM

CONTX: ContextVision publishes Webcast for the Q2 report 2025

Regulatory press release8/26/2025, 6:00 AM

ContextVision AB: Q2 interim report 2025 - Customers pressured by trade uncertainty - We continue to invest to build tomorrow's solutions

Press release8/26/2025, 6:00 AM

ContextVision AB: ContextVision publishes Webcast for the Q2 report 2025

Regulatory press release5/30/2025, 6:00 AM

CONTX: ContextVision and AMRA Medical join forces to advance multimodal imaging in liver disease diagnostics

Press release5/30/2025, 6:00 AM

ContextVision AB: ContextVision and AMRA Medical join forces to advance multimodal imaging in liver disease diagnostics

Regulatory press release5/13/2025, 1:45 PM

ContextVision AB: BULLETIN FROM THE ANNUAL GENERAL MEETING OF CONTEXTVISION AB (PUBL)

Regulatory press release5/7/2025, 6:00 AM

CONTX: ContextVision publishes Webcast for the Q1 report 2025

Regulatory press release5/7/2025, 6:00 AM

ContextVision AB: Q1 interim report 2025 - Executing on our strategy for Image Quality and Data Quality

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.